Page last updated: 2024-09-03

imatinib mesylate and Bone Marrow Diseases

imatinib mesylate has been researched along with Bone Marrow Diseases in 9 studies

Research

Studies (9)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	7 (77.78)	29.6817
2010's	2 (22.22)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Bergeron, A; Cony-Makhoul, P; Corm, S; Dubruille, V; Nicolini, FE; Rea, D; Rigal-Huguet, F	1
Hong, FS; Mitchell, CA; Zantomio, D	1
Akcakaya, MO; Aras, Y; Bilgic, B; Unal, OF; Unal, SN	1
Kumar, L; Kumari, M; Lokeshwar, N	1
Koseki, M; Matsue, K; Takeuchi, M; Uryu, H	1
Appio, L; Campiotti, L; Codari, R; Maria Grandi, A; Solbiati, F; Ultori, C; Venco, A	1
Bonvalot, S; Cesne, AL; Cioffi, A; Domont, J; Pechoux, CL; Vanel, D	1
Abrey, LE; Gavrilovic, IT; Lassman, AB; Rosenfeld, SS; Shah, GD; Silver, JS	1
Junaid, A; Khan, KA; Mukhtar, K; Siddiqui, NS; Siddiqui, S	1

Trials

1 trial(s) available for imatinib mesylate and Bone Marrow Diseases

Article	Year
Myelosuppression in patients benefiting from imatinib with hydroxyurea for recurrent malignant gliomas. Journal of neuro-oncology, 2007, Volume: 85, Issue:2 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Bone Marrow; Bone Marrow Diseases; Brain Neoplasms; Glioblastoma; Humans; Hydroxyurea; Imatinib Mesylate; Male; Middle Aged; Neoplasm Recurrence, Local; Nucleic Acid Synthesis Inhibitors; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Retrospective Studies; Treatment Outcome	2007

Article

Year

Myelosuppression in patients benefiting from imatinib with hydroxyurea for recurrent malignant gliomas.

Journal of neuro-oncology, 2007, Volume: 85, Issue:2

Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Bone Marrow; Bone Marrow Diseases; Brain Neoplasms; Glioblastoma; Humans; Hydroxyurea; Imatinib Mesylate; Male; Middle Aged; Neoplasm Recurrence, Local; Nucleic Acid Synthesis Inhibitors; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Retrospective Studies; Treatment Outcome

2007

Other Studies

8 other study(ies) available for imatinib mesylate and Bone Marrow Diseases

Article	Year
[Guidelines for the management of dasatinib (Sprycel)-induced side effects in chronic myelogenous leukemia and Philadelphia positive acute lymphoblastic leukemias]. Bulletin du cancer, 2008, Volume: 95, Issue:9 Topics: Antineoplastic Agents; Benzamides; Bone Marrow; Bone Marrow Diseases; Dasatinib; Drug Resistance, Neoplasm; Female; France; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Piperazines; Pleural Effusion; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Pregnancy; Pyrimidines; Thiazoles	2008
Gelatinous transformation of the bone marrow as a late morphological change in imatinib mesylate treated chronic myeloid leukaemia. Pathology, 2010, Volume: 42, Issue:1 Topics: Adult; Alcian Blue; Antineoplastic Agents; Benzamides; Bone Marrow; Bone Marrow Diseases; Coloring Agents; Humans; Hyaluronic Acid; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Piperazines; Pyrimidines; Remission Induction	2010
Bone marrow necrosis secondary to imatinib usage, mimicking spinal metastasis on magnetic resonance imaging and FDG-PET/CT. Journal of neurosurgery. Spine, 2012, Volume: 16, Issue:1 Topics: Aged; Antineoplastic Agents; Benzamides; Bone Marrow; Bone Marrow Diseases; Diagnosis, Differential; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Magnetic Resonance Imaging; Multimodal Imaging; Necrosis; Piperazines; Positron-Emission Tomography; Pyrimidines; Spinal Neoplasms; Tomography, X-Ray Computed	2012
Severe bone marrow aplasia following imatinib mesylate in a patient with chronic myelogenous leukemia. Leukemia & lymphoma, 2005, Volume: 46, Issue:5 Topics: Antineoplastic Agents; Benzamides; Bone Marrow Diseases; Busulfan; Fatal Outcome; Female; Humans; Imatinib Mesylate; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Middle Aged; Mucormycosis; Piperazines; Pyrimidines	2005
Bone marrow necrosis associated with the use of imatinib mesylate in a patient with Philadelphia chromosome-positive acute lymphoblastic leukemia. Annals of hematology, 2006, Volume: 85, Issue:8 Topics: Aged; Antineoplastic Agents; Benzamides; Bone Marrow; Bone Marrow Diseases; Humans; Imatinib Mesylate; Male; Necrosis; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Pyrimidines	2006
Bone marrow necrosis related to imatinib mesylate therapy for cml bilineal blast crisis. Leukemia research, 2007, Volume: 31, Issue:12 Topics: Aged; Benzamides; Blast Crisis; Bone Marrow Diseases; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Necrosis; Piperazines; Pyrimidines	2007
Imatimid-induced bone marrow necrosis detected on MRI examination and mimicking bone metastases. Skeletal radiology, 2007, Volume: 36, Issue:9 Topics: Adult; Antineoplastic Agents; Benzamides; Bone Marrow Diseases; Bone Neoplasms; Diagnosis, Differential; Fatal Outcome; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Magnetic Resonance Imaging; Male; Necrosis; Pelvic Bones; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Remission Induction	2007
Imatinib-related bone marrow aplasia after complete cytogenetic response in chronic myeloid leukemia. Journal of the College of Physicians and Surgeons--Pakistan : JCPSP, 2008, Volume: 18, Issue:3 Topics: Antineoplastic Agents; Benzamides; Bone Marrow Diseases; Fatal Outcome; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines	2008